Relmada Therapeutics to Host Financial Results Conference Call
Relmada Therapeutics, Inc. (Nasdaq: RLMD), a pioneering clinical-stage biotechnology company, is prepared to discuss its financial results for the first quarter concluded on March 31, 2025. This important conference call and webcast is scheduled for a convenient time on Monday, May 12, 2025, at 4:30 PM ET. Participants are encouraged to join and learn about the company's progress and financial developments.
Key Details for the Upcoming Call
This conference call presents an opportunity for stakeholders to gain insights into Relmada's financial performance and future strategies. Interested participants can join the call by using the following dial-in numbers. For those in the U.S., the number is 1-877-407-0792, while international participants can dial 1-201-689-8263. The conference ID to access the call is 13753596. The company has also arranged for a webcast, accessible online, so that anyone can tune in from the comfort of their homes or offices.
Webcast Access and Replay Information
The webcast will provide a comprehensive overview of the financial results as well as recent advancements made by Relmada. A replay of the webcast will be made available shortly after the live event, ensuring that those unable to attend can still access the content. This replay will be found in the Investors section on the Relmada website.
About Relmada Therapeutics, Inc.
Founded with a vision of transforming the treatment landscape, Relmada Therapeutics is intensely focused on developing innovative breakthrough therapies aimed at enhancing the quality of life for patients suffering from serious conditions. One of its flagship investigational treatments, NDV-01, is currently undergoing evaluation in a Phase 2 study specifically targeted at High-Grade Non-Muscle Invasive Bladder Cancer. In tandem, the company is preparing to advance another significant therapy, sepranolone. This product is poised for Phase 2b studies focusing on compulsion-related disorders, which include Tourette’s Syndrome and Prader-Willi Syndrome, promising hope to those affected.
Investor and Media Contacts
If you have inquiries regarding investor relations or media coverage, you are encouraged to reach out to Brian Ritchie at LifeSci Advisors for investment-related matters. For media inquiries, the Corporate Communications team is available for assistance. Contact information for both can be found on the Relmada website.
Frequently Asked Questions
What will be discussed during the conference call?
The call will focus on the financial results for the first quarter of 2025 and the company's recent business advancements.
How can I access the conference call?
You can join the call by dialing 1-877-407-0792 for US participants or 1-201-689-8263 for international attendees.
Is there a way to listen to the call after it has finished?
Yes, a replay of the webcast will be available in the Investors section of the Relmada website shortly after the event concludes.
What is the primary focus of Relmada Therapeutics?
Relmada focuses on developing innovative therapeutic solutions to address serious health issues affecting targeted patient populations.
What are NDV-01 and sepranolone?
NDV-01 is an investigational treatment in a Phase 2 study for bladder cancer, while sepranolone is aimed at treating compulsion-related disorders and is ready to progress to Phase 2b trials.
